ЗАКЛЮЧЕНИЕ
В условиях туберкулеза макрофаги представляют ключевую клеточную популяцию, определяющую не только первичное взаимодействие с M. tuberculosis, но и дальнейший каскад патологических реакций, приводящих ко вторичной иммунологической недостаточности, а также неконтролируемой деструкции легочной паренхимы и диссеминации процесса.
ЛИТЕРАТУРА / REFERENCES
1. World Health Organization. Global Tuberculosis report. 2017.
2. Cliff J.M., Kaufmann S.H., McShane H., van Helden P., O'Garra A. The human immune response to tuberculosis and its treatment: a view from the blood. Immunol. Rev. 2015; 264 (1): 88-102.
3. Ziuzia Iu.R., Zimina V.N., Al'varesFigeroa M.V., Parkhomenko Iu.G., Dolgova E.A. The morphological characteristics of HIV-associated tuberculosis in relation to blood CD4+ lymphocyte counts. Arkh. Patol. 2014; Sept.-Oct.; 76 (5): 33-37.
4. Bhattacharya D., Danaviah S., Muema D.M., Akilimali N.A., Moodley P., Ndung'u T., Das G. Cellular аrchitecture of spinal granulomas and the immunological response in tuberculosis patients coinfected with HIV. Front. Immunol. 2017; 8: 1120.
5. Huygen K. The immunodominant T-cell epitopes of the mycolyl-transferases of the antigen 85 complex of M. tuberculosis. Front. Immunol. 2014; 5: 1-11.
6. Jasenosky L.D., Scriba T.J., Hanekom W.A., Goldfeld A.E. T cells and adaptive immunity to Mycobacterium tuberculosis in humans. Immunol. Rev. 2015; 264: 74-87.
7. Martinez F.O., Gordon S. The Ml and M2 paradigm of macrophage activation: time for reassessment. F1000 Prime Rep. 2014; 6: 13. Published 2014 Mar. 3.
8. Italiani P., Boraschi D. From monocytes to M1/M2 macrophages: phenotypical vs. functional differentiation. Front. Immunol. 2014; 5: 514.
9. Serena Y.S. Tan, Mark A. Developmental origin of lung macrophage diversity. Krasnow Development. 2016; 143: 1318-1327.
10. Dorhoi A., Kaufmann S.H. Pathology and immune reactivity: understanding multidimensionality in pulmonary tuberculosis. Semin. Immunopathol. 2016; Mar.; 38 (2): 153-166. Epub. 2015, Oct. 5.
11. Янин В.Л., Бондаренко О.М., Сазонова Н.А. Методы исследования в цитологии и гистологии: учебнометодическое пособие. Ханты-Мансийск: БУ «Ханты- Мансийская государственная медицинская академия», 2015: 65. [Yanin V.L., Bondarenko O.M., Sazonova N.A. Methods of research in cytology and histology: teaching guide. Khanty-Mansiysk: BU “Khanty-Mansiysk State Medical Academy” Publ., 2015: 65 (in Russ.)].
12. Kim P.S., Makhene M., Sizemore C., Hafner R. Viewpoint: Challenges and opportunities in tuberculosis research. J. Infect. Dis. 2012; 205 Suppl. 2: 347-352.
13. Lyadova I.V., Panteleev A.V. Th1 and Th17 сells in tuberculosis: protection, pathology, and biomarkers. Mediators Inflamm. 2015; 2015: 8545-8507.
14. Aryanpur M., Mortaz E., Masjedi M.R., Tabarsi P., Garssen J., Adcock I.M., Mozafarian A. and Sharifi H. Reduced phagocytic capacity of blood monocyte/macrophages in tuberculosis patients is further reduced by smoking. Iranian Journal of Allergy, Asthma and Immunology. 2016; 15 (3): 174-182.
15. Yakar H.I., Gunen H., Pehlivan E., Aydogan S. The role of tuberculosis in COPD. Int. J. Chron. Obstruct. Pulm- on. Dis. 2017; 12: 323-329.
16. Kim H.J., Baek S., Kim H.J. The impact of smoking on airflow limitation in subjects with history of asthma and inactive tuberculosis. PLoS One. 2015; 10 (4).
17. Chistiakov D.A., Killingsworth M.C., Myasoedova V.A., Orekhov A.N., Bobryshev Y.V. CD68/macrosialin: not just a histochemical marker. Laboratory Investigation. 2017; 97: 4-13.
18. Gordon S., Plbddemann A., Martinez Estrada F. Macrophage heterogeneity in tissues: phenotypic diversity and functions. Immunol. Rev. 2014; 262: 36-55.
19. Italiani P., Boraschi D. From Monocytes to M1/M2 Macrophages: phenotypical vs functional differentiation. Front. Immunol. 2014; 5: 514.
20. Chavez-Galan L., Olleros M.L., Vesin D., Garcia I. Much More than M1 and M2 Macrophages, there are also CD169(+) and TCR(+) macrophages. Front. Immunol. 2015; 6: 263.
21. Голубинская Е.П., Филоненко Т.Г., Кальфа М.А.,
22. Ермола Ю.А. Морфологические особенности ангиогенеза при фиброзно-кавернозном туберкулезе. Крымский журнал экспериментальной и клинической медицины. 2018; 8 (1): 16-19. [Golubinskaya E.P.,
23. Filonenko T.G., Kalfa M.A., Ermola Yu. A. Morphological features of angiogenesis in fibrous cavernous pulmonary tuberculosis. Crimean Journal of Experimental and Clinical Medicine. 2018; 8 (1): 16-19 (in Russ.)].
24. Голубинская Е.П., Крамарь Т.В. Морфофункциональное обоснование таргетной терапии блокаторами ангиогенеза при фиброзно-кавернозном туберкулезе. Материалы международного форума «Биотехнология: состояние и перспективы развития». 2018, май 23-25; Москва, Россия: 400-402. [Golubinskaya E.P., Kramar T.V. Morphofunctional substantiation of targeted therapy with blockers of angiogenesis in fibrous cavernous pulmonary tuberculosis. Materials of the international forum “Biotechnology: state and prospects of development”. 2018, May 23-25; Moscow, Russia: 400-402 (in Russ.)].